These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20515568)

  • 1. Xenotransplantation of hepatocytes in rats with acute liver failure using sirolimus for immunosuppression.
    Lytras D; Papalois A; Tsaroucha AK; Papagoras D; Kyriazanos J; Lambropoulou M; Giannakou N; Galanos A; Simopoulos CE
    J Int Med Res; 2010; 38(2):546-57. PubMed ID: 20515568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil and sirolimus in hepatocyte transplantation in an experimental model of toxic acute liver failure.
    Loukopoulos I; Sfiniadakis I; Pillai A; Konstantoulakis M; Androulakis G; Bonatsos V; Zografos G; Papalois A
    J Invest Surg; 2014 Aug; 27(4):205-13. PubMed ID: 24564245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.
    Bai S; Brunner LJ; Stepkowski SM; Napoli KL; Kahan BD
    Transplantation; 2001 Jun; 71(11):1585-92. PubMed ID: 11435969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressant use without bone loss--implications for bone loss after transplantation.
    Goodman GR; Dissanayake IR; Sodam BR; Gorodetsky E; Lu J; Ma YF; Jee WS; Epstein S
    J Bone Miner Res; 2001 Jan; 16(1):72-8. PubMed ID: 11149492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation.
    Papagoras D; Papalois A; Tsaroucha A; Lytras D; Kyriazanos J; Giannakou N; Laftsidis P; Simopoulos C
    World J Gastroenterol; 2007 Mar; 13(9):1435-7. PubMed ID: 17457977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.
    Sereno J; Parada B; Rodrigues-Santos P; Lopes PC; Carvalho E; Vala H; Teixeira-Lemos E; Alves R; Figueiredo A; Mota A; Teixeira F; Reis F
    Transplant Proc; 2013 Apr; 45(3):1149-56. PubMed ID: 23622648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
    Oberbauer R; Hutchison B; Eris J; Arias M; Claesson K; Mota A; Kreis H; Kleinman L; Wang F; Chen J; Revicki DA;
    Transplantation; 2003 Apr; 75(8):1277-85. PubMed ID: 12717216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sirolimus alone or in combination with cyclosporine A on renal ischemia/reperfusion injury.
    Pereira BJ; Castro I; Burdmann EA; Malheiros DM; Yu L
    Braz J Med Biol Res; 2010 Aug; 43(8):737-44. PubMed ID: 20549136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
    J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
    Guba M; Pratschke J; Hugo C; Krämer BK; Pascher A; Pressmar K; Hakenberg O; Fischereder M; Brockmann J; Andrassy J; Banas B; Jauch KW;
    Transpl Int; 2012 Apr; 25(4):416-23. PubMed ID: 22320241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood.
    Barten MJ; Streit F; Boeger M; Dhein S; Tarnok A; Shipkova M; Armstrong VW; Mohr FW; Oellerich M; Gummert JF
    Transplantation; 2004 Apr; 77(8):1154-62. PubMed ID: 15114077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions.
    Napoli KL; Wang ME; Stepkowski SM; Kahan BD
    Ther Drug Monit; 1998 Apr; 20(2):123-33. PubMed ID: 9558125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.